Your browser doesn't support javascript.
loading
Clinical efficacy and safety of montelukast combined with budesonide in the treatment of children / 中国生化药物杂志
Chinese Journal of Biochemical Pharmaceutics ; (6): 137-138,140, 2017.
Artículo en Chino | WPRIM | ID: wpr-615904
ABSTRACT
Objective To investigate the clinical efficacy and safety of montelukast combined with budesonide in the treatment of children with asthma. Methods 70 cases of children with asthma were randomly divided into group A and group B, included 35 cases in each group. Group A was treated with single budesonide and Group B was given montelukast combined with budesonide. The clinical efficacy of two groups of asthma was compared, the body temperature returned to normal time, the time of wheezing disappeared, the normal time of the laboratory index, the normal time of the chest radiograph, the inflammatory factors and the lung function indexes and the side effects. Results The clinical curative effect of group B was higher than that of group A(P<0.05); Body temperature in group B returned to normal time, the time of wheezing disappeared, the normal time of laboratory index was shorter than that of group A(P<0.05); Inflammatory factors and lung function were similar. After intervention, the inflammatory factors and lung function of group B were better than those of group A(P<0.05). There were no obvious side effects in the two groups. Conclusion The clinical efficacy and safety of montelukast combined with budesonide in the treatment of children with asthma can improve the symptoms of children, cause the symptoms to recite in a short time, reduce the inflammatory factors, improve lung function, no obvious adverse reactions, safety effective.

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Chino Revista: Chinese Journal of Biochemical Pharmaceutics Año: 2017 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Chino Revista: Chinese Journal of Biochemical Pharmaceutics Año: 2017 Tipo del documento: Artículo